161 related articles for article (PubMed ID: 27394672)
21. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
Sánchez-Moya AI; Dauden E
J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
[TBL] [Abstract][Full Text] [Related]
22. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
[TBL] [Abstract][Full Text] [Related]
23. Performance of QuantiFERON®-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs.
Gabriele F; Trachana M; Simitsopoulou M; Pratsidou-Gertsi P; Iosifidis E; Pana ZD; Roilides E
World J Pediatr; 2017 Oct; 13(5):472-478. PubMed ID: 28646434
[TBL] [Abstract][Full Text] [Related]
24. Mycobacterial interferon-γ release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome.
Scrivo R; Sauzullo I; Mengoni F; Priori R; Coppola M; Iaiani G; DI Franco M; Vullo V; Mastroianni CM; Valesini G
J Rheumatol; 2013 Feb; 40(2):157-65. PubMed ID: 23204217
[TBL] [Abstract][Full Text] [Related]
25. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
[TBL] [Abstract][Full Text] [Related]
26. Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.
Yamamoto S; Nagatani K; Sato T; Iwamoto M; Takatori S; Minota S
Int J Rheum Dis; 2017 May; 20(5):584-588. PubMed ID: 28524434
[TBL] [Abstract][Full Text] [Related]
27. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
28. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.
Lee H; Park HY; Jeon K; Jeong BH; Hwang JW; Lee J; Cha HS; Koh EM; Kang ES; Koh WJ
PLoS One; 2015; 10(3):e0119260. PubMed ID: 25746854
[TBL] [Abstract][Full Text] [Related]
29. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.
Calzada-Hernández J; Anton-López J; Bou-Torrent R; Iglesias-Jiménez E; Ricart-Campos S; Martín de Carpi J; ; Torrente-Segarra V; Sánchez-Manubens J; Giménez-Roca C; Rozas-Quesada L; Juncosa-Morros MT; Fortuny C; Noguera-Julian A
Pediatr Rheumatol Online J; 2015 Dec; 13():54. PubMed ID: 26635208
[TBL] [Abstract][Full Text] [Related]
30. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy.
Singanayagam A; Manalan K; Sridhar S; Molyneaux PL; Connell DW; George PM; Kindelerer A; Seneviratne S; Lalvani A; Wickremasinghe M; Kon OM
Thorax; 2013 Oct; 68(10):955-61. PubMed ID: 23976779
[TBL] [Abstract][Full Text] [Related]
32. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.
Sellam J; Hamdi H; Roy C; Baron G; Lemann M; Puéchal X; Breban M; Berenbaum F; Humbert M; Weldingh K; Salmon D; Ravaud P; Emilie D; Mariette X;
Ann Rheum Dis; 2007 Dec; 66(12):1610-5. PubMed ID: 17456528
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Medina-Gil C; Dehesa L; Vega A; Kerdel F
Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
[TBL] [Abstract][Full Text] [Related]
34. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
35. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
36. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
[TBL] [Abstract][Full Text] [Related]
37. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
[TBL] [Abstract][Full Text] [Related]
40. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
Kim YJ; Kim YG; Shim TS; Koo BS; Hong S; Lee CK; Yoo B
Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
